Bio-Path completes second dose cohort in Phase 1/1b trial of BP1002 in AML

BIO-PATH HOLDINGS, INC.

Second dose cohort (40 mg/m²) completed in dose escalation for refractory/relapsed AML patients, including venetoclax-resistant.
Trial will pause for FDA data review; next planned dose is 60 mg/m² in monotherapy.
BP1002 targets Bcl-2 at mRNA level, may overcome venetoclax resistance; preclinical data showed potent inhibition.
Phase 1b combination with decitabine expected after monotherapy cohorts; enrollment rates described as good.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.